News
Follow along for a week of easy, diabetes-friendly meals because eating for healthy blood sugar levels doesn’t have to be so ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro pen, its widely used diabetes and weight-loss drug. Available in six dosages, Mounjaro helps manage type 2 ...
Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment options.
Cantor Fitzgerald maintained an Overweight rating on Eli Lilly, with a price target of $975, reflecting confidence in the company's weight loss drug pipeline despite some caution around amylin ...
Managing type 2 diabetes in the first month can feel overwhelming, but focusing on key areas like education, monitoring, ...
Bernstein SocGen Group has reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) ahead of the American Diabetes Association’s 85th Annual meeting.
Investing.com - Truist Securities maintained its buy rating and $1,038.00 price target on Eli Lilly (NYSE: LLY), a prominent player in the pharmaceutical industry with a market capitalization of ...
Is intermittent fasting appropriate for patients with diabetes? Experts discuss medication adjustments, hypoglycemia risks, ...
Bernstein SocGen Group has reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) ahead of the American Diabetes Association’s 85th Annual meeting. Currently trading at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results